CID is 2466
synonyms found at PubChem are:
bufexamac, 2438-72-4, Bufexamic acid, Parfenac, 2-(4-Butoxyphenyl)-N-hydroxyacetamide, Droxaryl, Feximac, Malipuran, Mofenar, Parfenal, Bufexamaco, Bufexamacum, Flogicid, Norfemac, Paraderm, Anderm, 4-Butoxy-N-hydroxybenzeneacetamide, p-Butoxyphenylacetohydroxamic acid, 4-Butoxyphenylacetohydroxamic acid, Flogocid N plastigel, Acide p-butoxyphenylacethydroxamique, 2-(p-Butoxyphenyl)-acetohydroxamic acid, Bufessamac [DCIT], Bufexamacum [INN-Latin], Bufexamaco [INN-Spanish], 2-(p-Butoxyphenyl)acetohydroxamic acid, Benzeneacetamide, 4-butoxy-N-hydroxy-, CP 1044 J3, UNII-4T3C38J78L, CP 1044, CHEBI:31317, Bufexamac [INN:BAN:DCF:JAN], EINECS 219-451-1, ACETOHYDROXAMIC ACID, 2-(p-BUTOXYPHENYL)-, 2-(4-butoxyphenyl)acetohydroxamic acid, BRN 2646848, CHEMBL94394, MLS000028409, Acide p-butoxyphenylacethydroxamique [French], MXJWRABVEGLYDG-UHFFFAOYSA-N, 4T3C38J78L, CP-1044-J3, J3, 2-(4-butoxyphenyl)ethanehydroxamic acid, NCGC00016611-01, SMR000058407, CAS-2438-72-4, DSSTox_CID_25368, DSSTox_RID_80831, DSSTox_GSID_45368, Bufessamac, Droxarol, ML392, SR-01000003067, bufexamicacid, p-Butoxyphenylacethydroxamic Acid, Bufexamac,(S), Prestwick_676, Anderm (TN), Spectrum_001754, Bufexamac (JAN/INN), AC1L1DQQ, AC1Q2XHW, AC1Q5QCV, Opera_ID_1503, Prestwick0_000243, Prestwick1_000243, Prestwick2_000243, Prestwick3_000243, Spectrum2_001457, Spectrum3_000938, Spectrum4_001037, Spectrum5_001117, D02HXS, Epitope ID:180855, cid_2466, cp1044j3, REGID_for_CID_2466, SCHEMBL25215, BSPBio_000026, KBioGR_001593, KBioSS_002234, cp1044, MLS001148632, Bufexamac, analytical standard, Butoxyphenylacethydroxamic Acid, DivK1c_000108, SPECTRUM1502003, SPBio_001353, SPBio_002245, BPBio1_000030, GTPL7498, 4-butoxyphenylacetohydroxamicacid, DTXSID7045368, CTK8F8354, HMS500F10, KBio1_000108, KBio2_002234, KBio2_004802, KBio2_007370, KBio3_001976, acidep-butoxyphenylacethydroxamique, MolPort-001-846-212, NINDS_000108, 4-butoxy-n-hydroxy-benzeneacetamid, HMS1568B08, HMS1921B18, HMS2095B08, HMS2235I13, HMS3371K16, HMS3656H16, HMS3712B08, KUC105648N, Pharmakon1600-01502003, ACT07664, HY-B0494, KS-00000XL3, ZINC3871797, Para-butoxyphenylacetohydroxamic acid, Tox21_110522, BDBM50015144, BG0111, CCG-39191, NSC758153, s3023, SBB056991, 2-(p-butoxyphenyl)-acetohydroxamicaci, Bufexamac 1.0 mg/ml in Acetonitrile, AKOS015895401, KUC105648N-02, KUC105648N-03, Tox21_110522_1, API0001778, CS-2615, DB13346, KSC-10-210, MCULE-8477153639, NSC-758153, IDI1_000108, KSC-390-003, NCGC00016611-02, NCGC00016611-03, NCGC00016611-04, NCGC00016611-05, NCGC00016611-06, NCGC00016611-07, NCGC00016611-09, NCGC00016611-10, NCGC00021813-03, NCGC00021813-04, 2-(4-Butoxy-phenyl)-N-hydroxy-acetamide, 2-(4-Butoxyphenyl)-N-hydroxyacetamide #, AC-18729, AJ-46354, AN-50915, AS-12207, LS-13084, SC-13711, KSC-285-073-1, SBI-0051694.P002, AB0005884, AX8118941, KB-222467, AB00052252, B1443, B4179, FT-0603607, ST24027540, ST50993888, Benzeneacetamide, 4-butoxy-N-hydroxy- (9CI), D01271, J10267, K-6542, AB00052252_19, AB00052252_20, I06-0661, J-015485, SR-01000003067-3, SR-01000003067-4, BRD-K36660044-001-15-0, Bufexamac, European Pharmacopoeia (EP) Reference Standard, A4Z